Immunotherapy News and Research

Latest Immunotherapy News and Research

CIK treatment enhances survival in early and advanced colorectal cancer

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent malignant tumor worldwide.

24 Jun 2025

Bispecific antibodies offer new hope for resistant NSCLC patients

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting for nearly 85% of all lung cancer cases.

23 Jun 2025

New lab method accelerates diagnosis of genetic disorders of the immune system

A new laboratory method developed by researchers at Columbia University Vagelos College of Physicians and Surgeons may now help physicians more quickly diagnose patients with suspected genetic disorders of the immune system, many who have been trapped in diagnostic limbo for years.

20 Jun 2025

Immune changes predict heart risks in cancer patients on checkpoint inhibitors

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint inhibitors.

20 Jun 2025

Targeted nanoparticles enable in vivo production of CAR T cells for cancer therapy

Researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells.

20 Jun 2025

Epigenetic dysregulation drives hepatocellular carcinoma development

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide.

19 Jun 2025

Full tumor DNA sequencing becomes standard for children with cancer

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first.

19 Jun 2025

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

17 Jun 2025

Rare pancreatic cancer patients show remarkable outcomes with immunotherapy

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence."

17 Jun 2025

Breakthrough therapy targets aggressive bladder cancer variant

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

17 Jun 2025

Researchers identify a new treatment strategy for neuroblastoma

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer.

16 Jun 2025

New computational tool uncovers hidden genetic mutations in proteins

Scientists at UCLA and the University of Toronto have developed an advanced computational tool, called moPepGen, that helps identify previously invisible genetic mutations in proteins, unlocking new possibilities in cancer research and beyond.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025

Bringing microbiome science into everyday clinical care

The article summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors.

13 Jun 2025

Boosting CAR T cell survival to improve solid tumor therapy

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

13 Jun 2025